GlassScriptPhysician profile
Derek Hundt
NPI 1518527084
$4,668.06
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,419 · 2022: $1,372 · 2023: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,326.85 | 2021 | |
| Abbvie INC. | $473.42 | 2021-2023 | |
| Novo Nordisk INC | $321.17 | 2022-2023 | Wegovy, Saxenda, Ozempic |
| Pfizer INC. | $290.79 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.70 | 2021-2023 | Xifaxan |
| Amgen INC. | $255.12 | 2021-2023 | Otezla, Repatha |
| Lilly USA, LLC | $195.57 | 2022-2023 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.13 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $157.09 | 2021-2022 | |
| Astellas Pharma US INC | $95.15 | 2021-2023 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $93.12 | 2021-2023 | Shingrix |
| Merck Sharp & Dohme LLC | $87.75 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $85.58 | 2023 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $83.12 | 2021-2023 | |
| Nabriva Therapeutics, Plc | $82.90 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $78.76 | 2022-2023 | |
| Almatica Pharma LLC | $55.97 | 2021 | |
| Antares Pharma, INC. | $55.91 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Idorsia Pharmaceuticals US INC | $54.29 | 2022-2023 | Quviviq |
| Eisai INC. | $44.75 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.51 | 2022 | |
| Adlon Therapeutics L.P. | $38.52 | 2021 | |
| Noven Therapeutics, LLC | $38.15 | 2023 | Secuado |
| Teva Pharmaceuticals USA, INC. | $36.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.14 | 2021-2022 | |
| Corium, LLC | $31.89 | 2023 | Azstarys |
| Esperion Therapeutics, INC. | $23.33 | 2021 | |
| Althera Pharmaceuticals LLC | $21.11 | 2021 | |
| Supernus Pharmaceuticals, INC. | $19.88 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.21 | 2023 | Spravato |
| Currax Pharmaceuticals LLC | $17.63 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.31 | 2021 | |
| Philips North America LLC | $14.81 | 2022 | |
| Sanofi Pasteur INC. | $14.41 | 2022 | |
| Dexcom, INC. | $13.05 | 2021 | |
| Genentech USA, INC. | $9.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Hundt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.